AI Verdict
RARE has stronger fundamentals based on our AI analysis.
RARE vs RAPP Fundamental Comparison
| Metric | RARE | RAPP |
|---|---|---|
| Revenue | $673.0M | N/A |
| Net Income | $-575.0M | $-111.5M |
| Net Margin | -85.4% | N/A |
| ROE | N/A | -23.0% |
| ROA | -37.5% | -21.8% |
| Current Ratio | 2.48x | 26.17x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-5.83 | $-2.86 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RARE vs RAPP: Frequently Asked Questions
Is RARE or RAPP a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RARE has stronger fundamentals. RARE is rated SELL (72% confidence) while RAPP is rated STRONG SELL (78% confidence). This is not investment advice.
How does RARE compare to RAPP fundamentally?
Ultragenyx Pharmaceutical Inc. has ROE of N/A vs Rapport Therapeutics, Inc.'s -23.0%. Net margins are -85.4% vs N/A respectively.
Which stock pays higher dividends, RARE or RAPP?
RARE has a dividend yield of N/A or no dividend while RAPP has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RARE or RAPP for long term?
For long-term investing, consider that RARE has SELL rating with 72% confidence, while RAPP has STRONG SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RARE vs RAPP?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RARE vs RAPP, the AI consensus favors RARE based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.